Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

ClinicalTrials.gov ID: NCT04277637

Public ClinicalTrials.gov record NCT04277637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.

Study identification

NCT ID: NCT04277637
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: BeOne Medicines; Industry
Enrollment: 437 participants

Conditions and interventions

Conditions

Mature B-Cell Malignancies

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 23, 2020
Primary completion: May 30, 2027
Completion: May 30, 2027
Last update posted: Jun 21, 2026

2020 – 2027

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 12

Facility	City	State	ZIP	Site status
UCLA Hematologyoncology	Los Angeles	California	90095-3075	—
Northwestern University	Chicago	Illinois	60611	—
University of Kansas Medical Center Research Institute	Kansas City	Kansas	66160-8500	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Mayo Clinic Rochester	Rochester	Minnesota	55905-0001	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
John Theurer Cancer Center Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Columbia University Medical Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center Mskcc	New York	New York	10065-6800	—
The James Cancer Hospital and Solove Research Institute At Ohio State University	Columbus	Ohio	43210-1240	—
Upmc Hillman Cancer Center(Univ of Pittsburgh)	Pittsburgh	Pennsylvania	15232-1309	—
Md Anderson Cancer Center	Houston	Texas	77030-3907	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109-4433	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04277637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 21, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04277637 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →